Astellas Pharma Inc.
Clinical trials sponsored by Astellas Pharma Inc., explained in plain language.
Global pharmaceutical company developing medicines.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New eye injection aims to slow vision loss from Age-Related macular degeneration Results expected Jun 2027 (estimated)
-
New drug targets Hard-to-Treat cancers with KRAS G12D mutation
Disease control Recruiting nowThis study tests a new drug called ASP3082 in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The trial has two parts: first, finding a safe dose of ASP3082 alone or with another drug; second, testing it with other cancer treatments. Up to …
Phase 1 • Sponsor: Astellas Pharma Inc • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Brain infusion trial hopes to restore movement in chronic stroke patients
Disease control Recruiting nowThis study tests a new drug called ASP2246 for adults who have trouble moving after a stroke. In the first part, small groups get increasing doses via brain surgery to check safety. In the second part, some get the drug and others get a sham surgery, with neither patient nor doct…
Phase 1/2 • Sponsor: Astellas Pharma Inc • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New drug targets KRAS mutations in advanced cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug called ASP5834 in people with advanced solid tumors that have certain changes in the KRAS gene. The study will first find a safe dose of ASP5834 given alone or with another drug (panitumumab) in people with colorectal cancer. Up to 364…
Phase 1 • Sponsor: Astellas Pharma Inc • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC